BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salvarani C, Sebastiani M, Dieude P, Garcia M, Deberdt W, Rogai V, de la Torre I, Inciarte-Mundo J, Balsa A. Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials. Rheumatol Ther 2021;8:1435-41. [PMID: 34184191 DOI: 10.1007/s40744-021-00332-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Nasonov EL, Ananyeva LP, Avdeev SN. Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology. Naučno-praktičeskaâ revmatologiâ 2022;60:517-534. [DOI: 10.47360/1995-4484-2022-1] [Reference Citation Analysis]
2 Baricitinib. Reactions Weekly 2022;1937:114-114. [DOI: 10.1007/s40278-022-29794-y] [Reference Citation Analysis]
3 Buschulte K, Kreuter M, Schneider U, Casteleyn V. „Enthusiast meets the Experienced“: Pneumo meets … Rheumatologie. Z Pneumologie 2022. [DOI: 10.1007/s10405-022-00483-9] [Reference Citation Analysis]
4 Narváez J, Díaz del Campo Fontecha P, Brito García N, Bonilla G, Aburto M, Castellví I, Cano-jiménez E, Mena-vázquez N, Nieto MA, Ortiz AM, Valenzuela C, Abad Hernández MÁ, Castrejón I, Correyero Plaza M, Francisco Hernández FM, Hernández Hernández MV, Rodríquez Portal JA. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment. Reumatología Clínica (English Edition) 2022. [DOI: 10.1016/j.reumae.2022.03.004] [Reference Citation Analysis]
5 Narváez J, Díaz del Campo Fontecha P, Brito García N, Bonilla G, Aburto M, Castellví I, Cano-jiménez E, Mena-vázquez N, Nieto MA, Ortiz AM, Valenzuela C, Abad Hernández MÁ, Castrejón I, Correyero Plaza M, Francisco Hernández FM, Hernández Hernández MV, Rodríquez Portal JA. Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 2: tratamiento. Reumatología Clínica 2022. [DOI: 10.1016/j.reuma.2022.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tardella M, Di Carlo M, Carotti M, Ceccarelli L, Giovagnoni A, Salaffi F. A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease. Inflammopharmacol. [DOI: 10.1007/s10787-022-00936-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev 2022;:103056. [PMID: 35121155 DOI: 10.1016/j.autrev.2022.103056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
8 Garton M, Kelly C, Wrexham Glyndwr University, Wrexham, UK, University of Newcastle upon Tyne, Newcastle, UK. Is Janus Kinase Inhibition the Future of the Management of Rheumatoid Arthritis-associated Interstitial Lung Disease? US Respiratory & Pulmonary Diseases 2022;7:38. [DOI: 10.17925/usrpd.2022.7.2.38] [Reference Citation Analysis]